Histone deacetylase inhibition modulates deoxyribonucleotide pools and enhances the antitumor effects of the ribonucleotide reductase inhibitor 3′-C-methyladenosine in leukaemia cells

International Journal of Oncology

Volumn 38, Issue 5, 2011, Pages 1427-1436

  Meli, Maria ^a   Tolomeo, Manlio ^a   Grifantini, Mario ^b   Mai, Antonello ^c   Cappellacci, Loredana ^b   Petrelli, Riccardo ^b   Rotili, Dante ^c   Ferro, Arianna ^a   Saiko, Philipp ^d   Szekeres, Thomas ^d   Dusonchet, Luisa ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; Hdac inhibitors; Leukaemia; ROS; RR inhibitors

Indexed keywords

3' C METHYLADENOSINE; ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; CASPASE 3; DEOXYRIBONUCLEOTIDE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; MC 1864; MC 1879; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; REACTIVE OXYGEN METABOLITE; RIBONUCLEOTIDE REDUCTASE; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA;

ADENOSINE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DEOXYRIBONUCLEOTIDES; G1 PHASE; HISTONE DEACETYLASE INHIBITORS; HL-60 CELLS; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA; REACTIVE OXYGEN SPECIES; RIBONUCLEOTIDE REDUCTASES;

EID: 79954993415     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.943     Document Type: Article

References (38)

1. Hellebrekers DMEI, Griffioen AW and van Engeland M: Dual targeting of epigenetic therapy in cancer. Biochim Biophys Acta 1775: 76-91, 2007. (Pubitemid 44895568)
2. Hess-Stumpp H: Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur J Cell Biol 84: 109-121, 2005.
3. McLaughlin F and La Thangue NB: Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol 68: 1139-1144, 2004.
4. Mehnert JM and Kelly WK: Histone deacetylase inhibitors: Biology and mechanism of action. Cancer J 13: 23-29, 2007.
5. Batty N, Malouf GG and Issa JPJ: Histone deacetylase inhibitors as antineoplastic agents. Cancer Lett 280: 192-200, 2009.
6. Campas-Moya C: Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today 45: 787-795, 2009.
7. Glaser KB: HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 74: 659-671, 2007.
8. Piekarz RL, Sackett DL and Bates SE: Histone deacetylase inhibitors and demethylating agents: Clinical development of histone deacetylase inhibitors in cancer therapy. Cancer J13: 30-39, 2007.
9. Carew J, Giles FJ and Nawrocki ST: Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 269: 7-17, 2008.
10. Bevins RL and Zimmer SG: It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. Cancer Res 65: 6957-6966, 2005. (Pubitemid 41060736)
11. Donadelli M, Costanzo C, Begelli S, et al: Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 1773: 1095-1106, 2007. (Pubitemid 46898677)
12. Fuino L, Bali P, Wittmann S, et al: Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2: 971-984, 2003.
13. Maggio SC, Rosato RR, Kramer LB, et al: The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukaemia cells. Cancer Res 64: 2590-2600, 2004. (Pubitemid 38523917)
14. Kramer OK, Knauer SK, Zimmermann D, Stauber RH and Heinzel T: Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene 27: 732-740, 2008. (Pubitemid 351186315)
15. Shao J, Zhou B, Chu B and Yen Y: Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 6: 409-431, 2006. (Pubitemid 44033390)
16. Franchetti P, Cappellacci L, Pasqualini M, et al: Antitumor activity of C-methyl-β-D-ribofuranosyladenine nucleoside ribonucleotide reductase inhibitors. J Med Chem 48: 4983-4989, 2005. (Pubitemid 41033138)
17. Savarino A, Mai A, Norelli S, et al: 'Shock and kill' effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 6: 52, 2009.
18. Webb JL: Effect of more than one inhibitor. In: Enzymes and Metabolic Inhibitors. Academic Press, New York, pp66-79, 1966.
19. Duke RC and Cohen JJ: Morphological and biochemical assays of apoptosis. In: Current Protocols in Immunology. Coligan JE and Kruisbeak AM (eds.), John Wiley & Sons, New York, p 3.17.1., 1992.
20. Darzynkiewicz Z, Bruno S, Del Bino G, et al: Features of apoptotic cells measured by flow cytometry. Cytometry 13: 795-798, 1992.
21. Garrett C and Santi DV: Arapid and sensitive high pressure liquid chromatography assay for deoxyribonucleoside triphosphates in cell extracts. Anal Biochem 99: 268-273, 1979. (Pubitemid 10160812)
22. Rosato RR, Almenara JA and Grant S: The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukaemia cells through a process regulated by generation of reactive oxygen species and induction of p21 CIP1/WAF1. Cancer Res 63: 3637-3645, 2003. (Pubitemid 36793047)
23. Lorenzo HK and Susin SA: Therapeutic potential of AIF-mediated caspase-independent programmed cell death. Drug Res Updat 10: 235-255, 2007.
24. Stimson L, Wood V, Khan O, Fotheringham S and La Thangue NB: HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol 20: 1293-1302, 2009.
25. Kurz EU, Wilson SE and Leader KB: The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II α expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther 1: 121-131, 2001.
26. Bianchi V, Pontis E and Reichard P: Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J Biol Chem 261: 16037-16042, 1986. (Pubitemid 17202856)
27. Zhu L, Zhou B, Chen X, Jiang H, Shao J and Yen Y: Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicarbazones for two forms of human ribonucleotide reductase. Biochem Pharmacol 78: 1178-1185, 2009.
28. Elford HL and van't Riet B: Inhibition of nucleoside diphosphate reductase by hydroxybenzohydroxamic acid derivatives. Pharmac Ther 29: 239-254, 1985. (Pubitemid 16168253)
29. Elford HL, Wampler GL and van't Riet B: New ribonucleotide reductase inhibitors with antineoplastic activity. Cancer Res 39: 844-851, 1979. (Pubitemid 9143275)
30. Henderson C and Brancolini C: Apoptotic pathways activated by histone deacetylase inhibitors: implication for the drug-resistant phenotype. Drug Res Updat 6: 247-256, 2003. (Pubitemid 37493781)
31. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C and Brancolini C: Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 278: 12579-12589, 2003. (Pubitemid 36800248)
32. Bouzar AB, Boxus M, Defoiche J, et al: Valproate synergizes with purine nucleoside analogs to induce apoptosis of B-chronic lymphocytic leukaemia cells. Br J Heamatol 144: 41-52, 2008.
33. Mitsiades N, Mitsiades CS, Richardson PG, et al: Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101: 4055-4062, 2003. (Pubitemid 36857886)
34. Ruefli AA, Ausserlechner MJ, Bernhard D, et al: The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci 98: 10833-10838, 2001. (Pubitemid 32878706)
35. Norberg E, Gogvadze V, Vakifahmetoglu H, Orrenius S and Zhivotovsky B: Oxidative modification sensitizes mitochondrial apoptosis-inducing factor to calpain-mediated processing. Free Radic Biol Med 48: 791-797, 2010.
36. Chua BT, Guo Kand Li P: Direct cleavage by the calcium-activated protease calpain can lead to inactivation of caspases. J Biol Chem 275: 5131-5135, 2000. (Pubitemid 30108915)
37. Goll DE, Thompson VF, Li H, Wei W and Cong J: The calpain system. Physiol Rev 83: 731-801, 2003. (Pubitemid 36828925)
38. Carraway HE and Gore SD: Addition of histone deacetylase inhibitors in combination therapy. J Clin Oncol 25: 1955-1956, 2007.